PRN: Medical Treatment of Glaucoma Looks Set to Improve, a New Report Concludes

Medical Treatment of Glaucoma Looks Set to Improve, a New Report Concludes [09-February-2016] LONDON, February 9, 2016 /PRNewswire/ -- European Ophthalmic Review, the peer-reviewed journal, has published an update on the medical treatment of glaucoma These proceedings are based on a symposium that was presented at the European Society of Ophthalmology 2015 Congress in Vienna, Austria on 8 June 2015.

Persone Nicola Cartridge
Luoghi Vienna, Austria, Londra
Argomenti cinema

09/feb/2016 14.00.54 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Medical Treatment of Glaucoma Looks Set to Improve, a New Report Concludes

 
[09-February-2016]
 

LONDON, February 9, 2016 /PRNewswire/ --

European Ophthalmic Review, the peer-reviewed journal, has published an update on the medical treatment of glaucoma

These proceedings are based on a symposium that was presented at the European Society of Ophthalmology 2015 Congress in Vienna, Austria on 8 June 2015. The symposium was arranged to bring together leaders in ophthalmology to explore advances in the medical treatment of glaucoma. Many patients with glaucoma require combination therapy. Fixed-dose combinations represent a significant improvement in the medical treatment of glaucoma, being advantageous in terms of their association with good compliance and elimination of the wash-out effect. While preservatives are a historic necessity, their use is associated with increased ocular surface disease and higher indirect cost. The novel preservative-free tafluprost/timolol fixed-dose combination provides mean diurnal intraocular pressure (IOP) lowering of up to 40% from baseline and demonstrates similar efficacy with other prostaglandin/timolol fixed-dose combination! s, is superior to its individual components and non-inferior to its individual components given concomitantly. The tafluprost/timolol fixed-dose combination is well-tolerated with low prevalence of hyperaemia. It is generally accepted that function loss follows structural damage and that normal-pressure glaucoma (NPG) and high-pressure glaucoma (HPG) represent that same disease, separated by an arbitrary pressure level. However, functional damage (pattern electroretinogram) is detectable prior to structural damage and NPG patients show less retinal nerve fibre layer and visual field loss compared with the same optic nerve head morphology HPG patients. NPG patients seem to lose connective tissue first whereas, in HPG, patients seem to lose retinal nerve fibres first. Thus, whether NPG and HPG are the same disease is an open question.

     (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO )

The full peer-reviewed, open-access article is available here:
http://doi.org/10.17925/EOR.2015.09.02.132

Note to the Editor

touchOPHTHALMOLOGY (a division of Touch Medical Media) publishes the European Ophthalmic Review, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of ophthalmology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.
http://www.touchOPHTHALMOLOGY.com

Providing practical opinion to support best practice for busy healthcare professionals.

For inquires please contact:

Nicola Cartridge
Managing Editor
Tel: +44(0)207-193-3186
E-mail: editor@touchmedicalmedia.com

 

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl